Related Experiment Video
Updated: Jun 4, 2025
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population
Stefan Wolf1, Matiar Madanchi2, Patrick Turko2,3
1Division of Plastic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Abstract:
Secondary lymphedema is a common sequel of oncologic surgery and presents a global health burden still lacking pharmacological treatment. The infiltration of the lymphedematous extremities with CD4+T cells influences lymphedema onset and emerges as a promising therapy target. Here, we show that the modulation of CD4+FOXP3+CD25+regulatory T (Treg) cells upon anti-CTLA4 treatment protects against lymphedema development in patients with melanoma and in a mouse lymphedema model. A retrospective evaluation of a melanoma patient registry reveals that anti-CTLA4 reduces lymphedema risk; in parallel, anti-CTLA4 reduces edema and improves lymphatic function in a mouse-tail lymphedema model. This protective effect of anti-CTLA4 correlates with a systemic expansion of Tregs, both in the animal model and in patients with melanoma. Our data thus show that anti-CTLA4 with its lymphedema-protective and anti-tumor properties is a promising candidate for more diverse application in the clinics.
Insights
Anti-CTLA4 therapy reduces secondary lymphedema risk by modulating regulatory T cells (Tregs). This treatment benefits melanoma patients and a mouse lymphedema model, offering a promising clinical application.
Area of Science:
- Immunology
- Oncology
- Vascular Biology
Background:
- Secondary lymphedema is a common, debilitating complication of cancer surgery with no effective pharmacological treatments.
- CD4+ T cell infiltration in lymphedematous tissues is implicated in disease onset, suggesting T cells as therapeutic targets.
- Regulatory T cells (Tregs) play a crucial role in immune homeostasis and may influence lymphedema development.
Purpose of the Study:
- To investigate the potential of anti-CTLA4 therapy in preventing and treating secondary lymphedema.
- To explore the role of regulatory T cells (Tregs) in the context of anti-CTLA4 treatment and lymphedema.
- To evaluate the dual efficacy of anti-CTLA4 in managing both lymphedema and melanoma.
Main Methods:
- Retrospective analysis of a melanoma patient registry treated with anti-CTLA4.
- Utilizing a mouse model to assess anti-CTLA4's effects on lymphedema development, edema, and lymphatic function.
- Quantifying systemic Treg expansion in both patients and the animal model following anti-CTLA4 treatment.
Main Results:
- Anti-CTLA4 treatment was associated with a reduced risk of secondary lymphedema in melanoma patients.
- In a mouse lymphedema model, anti-CTLA4 decreased edema and improved lymphatic function.
- A significant systemic expansion of regulatory T cells (Tregs) was observed in both mice and patients receiving anti-CTLA4.
Conclusions:
- Modulation of CD4+FOXP3+CD25+ regulatory T cells (Tregs) via anti-CTLA4 treatment demonstrates protective effects against secondary lymphedema.
- Anti-CTLA4 exhibits promising therapeutic potential for secondary lymphedema, alongside its established anti-tumor activity.
- This study supports the broader clinical application of anti-CTLA4 for its dual lymphedema-protective and anti-tumor benefits.
